Navigation Links
VIRxSYS Publishes New Study on RNA Therapy
Date:4/6/2009

d an immune response. The technology used to perform the albumin splicing process is owned by VIRxSYS and is known as spliceosomal mediated RNA trans-splicing, or SMaRT(TM). VIRxSYS now has 39 publications in top tier journals showing the effectiveness of SMaRT(TM) in a broad variety of applications. The company expects to begin testing this technology in human trials in the second half of 2010.

The study was headed by Madaiah Puttaraju, Ph.D., of VIRxSYS. The full citation for the study is: Wang J, Mansfield SG, Cote CA, Jiang PD, Weng K, Amar MJ, Brewer BH Jr, Remaley AT, McGarrity GJ, Garcia-Blanco MA, Puttaraju M. Trans-splicing into highly abundant albumin transcripts for production of therapeutic proteins in vivo. Mol Ther. 2009; 17(2):343-51; doi:10.1038/mt.2008.260. Drs. Amar, Brewer and Remaley were collaborators at the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health. Part of these studies was performed under a cooperative research and development agreement (CRADA) between VIRxSYS and the NHLBI.

About VIRxSYS

Founded in 1998, VIRxSYS is a private biotechnology company that focuses on the development of a novel lentiviral gene delivery platform technology for the treatment of serious diseases. The Company has exclusively licensed its patented, proprietary lentiviral technology platform from The Johns Hopkins University (JHU) in Baltimore, Maryland where the original research was conducted. The Company obtained its SMaRT(TM) technology from Intronn Inc. More information regarding VIRxSYS can be found at www.virxsys.com.

    Contact: Russell LaMontagne
    Phone:   212-255-5340
    E-mail:  russell@corinthgroup.com


'/>"/>
SOURCE VIRxSYS Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIRxSYS and Lentigen Announce Litigation Settlement
2. VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
3. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
4. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
5. Consortium publishes Phase II map of human genetic variation
6. The Lancet Publishes Vasogens ACCLAIM Results
7. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
8. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
9. Springer publishes anthology with the Nanoethics Group
10. The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results
11. Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of Chinas Ministry of Science and Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ... June 29, 2015 , ... The global ... during the forecast period (2015 to 2020). The market is mainly driven by ... corporate funding for R&D. However, lack of adequate healthcare and research infrastructure in ...
(Date:6/29/2015)... Md. , June 29, 2015  Neuralstem, Inc. ... cell technology to develop small molecule and cell therapy ... it has been approved for listing on the NASDAQ ... stock will continue to trade on the NYSE MKT ... on the NASDAQ Capital Market is expected to commence ...
(Date:6/29/2015)... NEW YORK , June 29, 2015   For ... of life sciences to assess their overall digital maturity ... to show that these companies are not maturing fast ... the healthcare industry in numerous ways overall and customers ... industries in terms of digital customer engagement.  ...
(Date:6/26/2015)... 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... all nominees listed in the management information circular ... 2015 Annual Meeting of Shareholders, held earlier today, ... the following 5 nominees proposed by management were ... until the Company,s next Annual Meeting of Shareholders ...
Breaking Biology Technology:Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3
... , , HONG KONG, Dec. 31 /PRNewswire-Asia-FirstCall/ ... CO ), China,s leading provider of cord blood ... storage services, today announced that the underwriters of its recent ... their over-allotment option, which will result in the issuance of ...
... NORTH BILLERICA, Mass., Dec. 29 Seahorse Bioscience, Inc., leader ... bioenergetics, announced that TheScientist magazine cited their XF96 ... A panel of scientific experts assembled by TheScientist ... the two energy pathways of the cell in a microplate, ...
... , EMERYVILLE, Calif., Dec. 29 ... of results from its study on the anti-tumor mechanism of ... International Journal of Cancer , describe the potential molecular ... BN107 on estrogen receptor negative (ER-) breast cancer cells. , ...
Cached Biology Technology:China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option 2China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option 3TheScientist Awards Seahorse XF96 Analyzer a Top Ten Innovation for 2009 2Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer 2Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer 3
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit DNA-Tests ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... neue STR-Testkits der Produktlinie Investigator ... in den Markt eingeführt. Die neuen Kits zur Erstellung ...
(Date:6/17/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that Xiaomi, one of the world,s largest mobile ... ® family of capacitive touchscreen solutions and ... for its latest smartphones, the Xiaomi Mi Note ... in-cell display solutions and DDICs in discrete display ...
(Date:6/16/2015)... CITY , June 16, 2015 /CNW Telbec/ ... their partnership centralized around the incorporation of handyem,s ... point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented model ... BIO International Conference at the Pennsylvania ... from June 15 th to 18 ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... or at least the nice temperate parts. They,ve spread into ... from Argentina, and no native ant species has been known ... Stanford University undergraduate students working on a class project have ... been using chemical warfare to combat the Argentine tide. ...
... of the liver in men, reveals a new study from ... Sweden, there is reason to fear that more people will ... the Sahlgrenska Academy and doctor at Sahlgrenska University Hospital. , ... the link between overweight and the risk of developing cirrhosis ...
... diet to the raw food diet, many health-conscious Americans now want ... But some of these dietary prescriptions make little sense for modern ... use of food and eating habits among prehistoric people. While ... many of our more modern foods and diets were developed for ...
Cached Biology News:Native ants use chemical weapons to turn back invading Argentine ants 2Native ants use chemical weapons to turn back invading Argentine ants 3Native ants use chemical weapons to turn back invading Argentine ants 4Overweight more harmful to the liver than alcohol in middle-aged men 2An 'all natural' diet? There's no such thing 2An 'all natural' diet? There's no such thing 3
Normal human serum, single donor...
... ISO 9001:2000 Certified USDA Research Registered ... SOP's Training AALAS Certified Technicians ... Procedures GLP Documentation Upon Request Focus ... point for all your custom immunology service ...
Human IL-17D Affinity Purified Polyclonal Ab...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Biology Products: